source
- Vor pays RemeGen $10M for long-acting addition to autoimmune pipelineVor Bio is paying RemeGen $10 million upfront in cash for rights to RC298 outside Greater China, adding a long-acting drug candidate to its BAFF/APRIL franchise.Fierce Biotech · 6h ago↗ source
- Kyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-celKyverna is halting work on a next-gen CD19 CAR-T therapy as the biotech seeks FDA approval for what could become the first CAR-T treatment for an autoimmune disease.Fierce Biotech · 6h ago↗ source
- Novartis' Zolgensma linked to tumors as FDA probes gene therapy and orders GLP-1 eye risk warningsNovartis confirmed that nine patients who received its Zolgensma gene therapy for spinal muscular atrophy have developed tumors, prompting the FDA to open an investigation into the approved treatme…